# 2025-06882: DEA Revokes Arizona Nurse's License Over Drug Violations

2025-06882, Svetlana Burtman, N.P.; Decision and Order, is a Federal Register notice from Justice Department, Drug Enforcement Administration published 2025-04-22, effective 2025-04-22; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2025-06882
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-06882
- Title: Svetlana Burtman, N.P.; Decision and Order
- Type: Notice
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 90 FR 16881
- Published: 2025-04-22
- Effective: 2025-04-22
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

DEA Revokes Arizona Nurse's License Over Drug Violations

## Summary

Svetlana Burtman, a nurse practitioner in Arizona, had her DEA registration suspended and is facing revocation because she broke important rules about handling controlled substances. The government found she gave out drugs from an unregistered location and didn’t keep proper records, which could risk public safety. This decision means she can’t legally dispense these drugs anymore, and her new clinic’s registration was also denied.

## Effects PRIA read

- DEA Registration Revoked for Practitioner: cost, high. The Drug Enforcement Administration agreed to revoke Svetlana Burtman’s DEA Certificate of Registration No. MB2645767 and suspended that registration after an Order to Show Cause on December 28, 2023. The Decision and Order (published April 22, 2025) means she can no longer legally dispense or admi…
- New Clinic Registration Denied: cost, medium. The DEA denied Respondent’s application for a separate registration for her Green Valley Clinic (application No. W23106194M), and the Agency found she dispensed controlled substances at that unregistered location. The Agency’s findings note she dispensed at Green Valley after July 19, 2023 and that…
- Separate Registration Required per Location: cost, medium. The Agency reaffirmed that each principal place of business where controlled substances are dispensed requires a separate DEA registration under 21 CFR 1301.12(a). The Decision points to the Green Valley Clinic as an unregistered location where dispensing occurred, citing dispensing logs and admiss…
- Strict Recordkeeping and Dispensing Log Rules Enforced: cost, medium. The Agency found Respondent failed to maintain complete, readily retrievable records of controlled substances received (citing 21 U.S.C. 827 and 21 CFR 1304.04/1304.21) and failed to keep required dispensing logs (21 CFR 1304.22(c)). The missing Tucson purchase invoice records and incomplete dispen…
- Must Accept Responsibility to Retain Registration: cost, low. The Decision reiterates that a registrant seeking to retain or regain a DEA registration must unequivocally accept responsibility for misconduct and demonstrate they will not reoffend. The Agency found Respondent minimized her unlawful conduct and did not meet that standard.

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-22843](https://policyrisk.com/federal-register/2026-22843): Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ep…, 2026-11-10
- [2026-22842](https://policyrisk.com/federal-register/2026-22842): Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sal…, 2026-11-10

## Sources
- [2025-06882 on federalregister.gov](https://www.federalregister.gov/documents/2025/04/22/2025-06882/svetlana-burtman-np-decision-and-order)
- [2025-06882 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-04-22/pdf/2025-06882.pdf)

## Related
- [Previous: 2025-06879, National Center for Advancing Translational Sciences; Notice of Closed Meeting](https://policyrisk.com/federal-register/2025-06879)
- [Next: 2025-06883, Information Collection Being Reviewed by the Federal Communications Commission…](https://policyrisk.com/federal-register/2025-06883)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-06882 (as of 2026-06-08).
